Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastrointest Pharmacol Ther. May 6, 2013; 4(2): 16-22
Published online May 6, 2013. doi: 10.4292/wjgpt.v4.i2.16
Table 1 Respondent variables and responses on each question n (%)
Questionn (%)DNKP value
Age (yr)0.190
< 3585 (21)
35-44114 (27)
45-54112 (27)
55-64105 (25)
Specialty0.028
Gastroenterology232 (56)
Hepatology184 (44)
Patients (n per year)23 (5)< 0.001
< 10141 (34)
11-20160 (38)
≥ 2092 (23)
Percent admitted to hospital39 (9)< 0.001
< 25%46 (12)
26%-50%74 (18)
51%-75%94 (23)
>75%163 (38)
Of admitted, percent through ER44 (12)< 0.001
< 50%81 (19)
51%-75%69 (16)
> 75%222 (53)
Percent needing liver biopsy for diagnosis48 (12)< 0.001
< 25%318 (76)
26%-50%29 (7)
> 50%21 (5)
Test AAH patients for HCV53 (13)< 0.001
Yes341 (82)
No22 (5)
Percent positive for HCV58 (14)0.015
< 20%156 (37)
≥ 20%202 (49)
Treatment for AH< 0.001
Often283 (68)
Rarely114 (27)
Never19 (5)
Drug preference for treatment< 0.001
Corticosteroids197 (47)
Pentoxifylline150 (37)
Combination60 (14)
No preference9 (2)
What makes you choose Pentoxifylline> 0.05
Infection or sepsis300 (72)
GI bleeding161
Renal failure125
Hepatitis B139
Hepatitis C94 (23)
Change in treatment policy with HCV84 (20)< 0.001
Yes83 (20)
No249 (60)
Treatment preference with concurrent HCV79 (19)< 0.001
Corticosteroids14 (3)
Pentoxifylline114 (27)
Either21 (5)
Same as without HCV180 (44)
No treatment8 (2)
Does HCV alter outcome of AAH80 (19)0.510
No174 (42)
Worse161 (39)
Better1 (0.2)
Does HCV affect treatment response with CS87 (21)< 0.001
No262 (63)
Worse65 (16)
Better2 (0.4)
Does HCV affect treatment response with PTX90 (22)< 0.001
No297 (71)
Worse3 (0.7)
Better26 (6)
Table 2 Effect of respondent variables on proportion of respondents being in consensus on each of the four specific questions related to management of hepatitis C virus infected alcoholic hepatitis patients
Respondent variableRoutine screening for HCV
HCV does not change treatment approach
HCV does not affect response to corticosteroids
HCV does not affect treatmentresponse to pentoxifylline
n (%)P valueOR (95%CI)n (%)P valueOR (95%CI)n (%)P valueOR (95%CI)n (%)P valueOR (95%CI)
Age (yr) < 35 35-44 45-54 ≥ 550.20.70.80.75
68 (92)151 (76)154 (83)159 (91)1
85 (90)0.8 (0.3-2.5)66 (73)1.3 (0.6-3)69 (77)0.6 (0.3-1.3)79 (89)0.9 (0.3-2.8)
99 (96)2.1 (0.5-8)73 (78)0.9 (0.4-2)75 (81)0.7 (0.3-1.6)85 (93)1.7 (0.5-6)
88 (97)2.5 (0.6-11)58 (72)1.4 (0.6-3)63 (79)0.6 (0.3-1.5)73 (91)1.3 (0.4-4.2)
Specialty GE HP0.370.50.20.55
183 (93)1135 (73)1135 (77)1160 (92)1
157 (95)1.5 (0.6-3.7)113 (77)0.8 (0.5-1.4)126 (83)0.7 (0.4-1.2)136 (90)1.3 (0.6-2.7)
Patients (n/yr) < 30 ≥ 300.290.60.20.38
299 (93)1221 (75)1232 (81)1259 (91)1
41 (98)2.9 (0.4-22.0)27 (71)1.3 (0.6-2.7)29 (73)1.6 (0.7-3.3)37 (95)0.5 (0.1-2.3)
HCV prevalence < 20% ≥ 20%0.480.30.20.81
148 (95)0.7 (0.3-1.8)104 (72)0.8 (0.5-1.3)119 (83)1.4 (0.8-2.5)129 (91)1.1 (0.5-2.4)
188 (93)1143 (77)1141 (77)1166 (91)1
Table 3 Effect of respondent variables on proportion of respondents being in consensus on all four questions related to management of hepatitis C virus infected alcoholic hepatitis patients
RespondentvariableConsensus on all four questions related tomanagement of HCV infected AH patients
n (%)P valueOR (95%CI)
Age (yr)
< 3537 (44)1
35-4452 (46)0.9 (0.5-1.8)
45-5458 (53)0.21.1 (0.6-3.1)
≥ 5544 (43)1.9 (0.5-4.3)
Specialty
GE125 (56)1
HP84 (47)0.371.4 (0.97-2.1)
Patients (n/yr)
< 30180 (52)1
≥ 3022 (49)0.291.1 (0.6-2.1)
HCV prevalence
< 20%71 (46)0.480.9 (0.6-1.4)
≥ 20%97 (48)1